For research use only. Not for therapeutic Use.
PF-07321332（Cat No.:I034512）, also known as nirmatrelvir, is an investigational antiviral drug developed by Pfizer for the treatment of COVID-19. It is an orally administered protease inhibitor that targets the viral 3CL protease (also known as Mpro). By inhibiting the activity of this protease, PF-07321332 aims to prevent viral replication and limit the spread of SARS-CoV-2, the virus responsible for COVID-19. PF-07321332 has shown promising results in preclinical and clinical studies and is being evaluated for its efficacy and safety in treating COVID-19 patients.
| Catalog Number | I034512 |
| CAS Number | 2628280-40-8 |
| Synonyms | Paxlovid; PF-07321332 |
| Molecular Formula | C23H32F3N5O4 |
| Purity | 98% |
| Target | CYP3A4/3CL/HIV-1 |
| Target Protein | P0DTD1 |
| Solubility | To be determined |
| Appearance | Solid |
| Storage | Dry, dark and at 2 - 8 °C for six months or -20°C for two years. |
| IC50 | 3CLPRO |
| IUPAC Name | (1R,2S,5S)-N-[(1S)-1-cyano-2-[(3S)-2-oxopyrrolidin-3-yl]ethyl]-3-[(2S)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide |
| InChI | InChI=1S/C23H32F3N5O4/c1-21(2,3)16(30-20(35)23(24,25)26)19(34)31-10-13-14(22(13,4)5)15(31)18(33)29-12(9-27)8-11-6-7-28-17(11)32/h11-16H,6-8,10H2,1-5H3,(H,28,32)(H,29,33)(H,30,35)/t11-,12-,13-,14-,15-,16+/m0/s1 |
| InChIKey | LIENCHBZNNMNKG-OJFNHCPVSA-N |
| SMILES | CC1([C@@H]2[C@H]1[C@H](N(C2)C(=O)[C@H](C(C)(C)C)NC(=O)C(F)(F)F)C(=O)N[C@@H](C[C@@H]3CCNC3=O)C#N)C |
